Skip to main content
. 2023 Sep 5;35(1):e5. doi: 10.3802/jgo.2024.35.e5

Table 2. Detailed characteristics of the six patients with synchronous/metachronous endometrial and colorectal cancers accompanied by loss of MMR proteins and diagnosed with Lynch syndrome.

Patient identifier Age at cancer diagnosis (yr) Family history Disease stage Loss of MMR proteins Germline pathogenic/likely pathogenic mutations or epimutations
EC CRC EC CRC EC CRC Blood or non-tumor tissue specimens
#9 71 60 Yes IIIC1 IIA MLH1, PMS2 MLH1, PMS2 MLH1 (p.Q346H)
#21* 53 71 Yes II IIB MLH1, PMS2 MLH1, PMS2 MLH1 (p.R497Pfs*6)
#28 59 52 Yes IA IIIA MLH1, PMS2 MLH1, PMS2 MLH1 (p.T117M)
#5 55 57 Yes IA IIIC MSH2, MSH6 MSH2, MSH6 MSH2 (splicing:c.1076+1G>T)
#22 55 55 Yes IA IIB MSH2, MSH6 MSH2, MSH6 MSH2 (p.R227Kfs*3)
#31 55 56 Yes IA I MSH6 MSH6 MSH6 (p.G685D)
#15 60 65 Yes IA IIIB MLH1, PMS2 MLH1, PMS2 MLH1 promoter hypermethylation

CRC, colorectal cancer; EC, endometrial cancer; MMR, mismatch repair.

*Patient also diagnosed with gastric cancer.

Patient also diagnosed with liver cancer.